Spyre Therapeutics Inc. (SYRE) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh money.
Spyre Therapeutics Inc. (SYRE) slipped -0.79% to $98.96 as options desks priced 52% call premium vs. 48% put protection around the $97 max-pain magnet. Stretched risk/reward at current multiples (-20% return on capital) under elevated 10-year interest-rate pressure.
Spyre Therapeutics has seen its share price move sharply in recent years, so the question now is whether a US$90.33 stock is adequately supported by what sits on its balance sheet. With the market focused on new inflamma
Spyre Therapeutics' (SYRE) combination therapy approach for inflammatory bowel disease gained furthe
BTIG analyst Julian Harrison reiterates Spyre Therapeutics (NASDAQ:SYRE) with a Buy and maintains $121 price target.
WALTHAM, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +17.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SYRE today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SYRE. Explore sector supply chains on /butterfly.
Why SYRE Stock slipped -0.79% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-20% return on capital) under elevated 10-year interest-rate pressure.